EHA 2026 | Week 144 analysis of the ASC4FIRST trial: asciminib in newly diagnosed chronic phase CML
Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, presents the findings from the week 144 analysis of the ASC4FIRST (NCT04971226) trial evaluating asciminib in newly diagnosed chronic phase chronic myeloid leukemia (CML), highlighting its superior efficacy compared to imatinib and second-generation tyrosine kinase inhibitors, with improved rates of deep molecular response. Prof. Hughes also notes that the safety and tolerability profile of asciminib remains favorable. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
